CN101663033B - 作为smo拮抗剂的三唑衍生物 - Google Patents

作为smo拮抗剂的三唑衍生物 Download PDF

Info

Publication number
CN101663033B
CN101663033B CN2008800127274A CN200880012727A CN101663033B CN 101663033 B CN101663033 B CN 101663033B CN 2008800127274 A CN2008800127274 A CN 2008800127274A CN 200880012727 A CN200880012727 A CN 200880012727A CN 101663033 B CN101663033 B CN 101663033B
Authority
CN
China
Prior art keywords
compound
cancer
methyl
bicyclo
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008800127274A
Other languages
English (en)
Chinese (zh)
Other versions
CN101663033A (zh
Inventor
J·M·巴尔科维克
R·蒂林格尔
S·T·沃德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN101663033A publication Critical patent/CN101663033A/zh
Application granted granted Critical
Publication of CN101663033B publication Critical patent/CN101663033B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2008800127274A 2007-04-18 2008-04-15 作为smo拮抗剂的三唑衍生物 Active CN101663033B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92501807P 2007-04-18 2007-04-18
US60/925,018 2007-04-18
PCT/US2008/004862 WO2008130552A1 (en) 2007-04-18 2008-04-15 Triazole derivatives which are smo antagonists

Publications (2)

Publication Number Publication Date
CN101663033A CN101663033A (zh) 2010-03-03
CN101663033B true CN101663033B (zh) 2013-01-16

Family

ID=39433852

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800127274A Active CN101663033B (zh) 2007-04-18 2008-04-15 作为smo拮抗剂的三唑衍生物

Country Status (12)

Country Link
US (1) US7691887B2 (https=)
EP (1) EP2136803B1 (https=)
JP (1) JP5498936B2 (https=)
CN (1) CN101663033B (https=)
AR (1) AR066063A1 (https=)
AT (1) ATE555785T1 (https=)
AU (1) AU2008241527B2 (https=)
CA (1) CA2683946C (https=)
CL (1) CL2008001074A1 (https=)
PE (1) PE20090806A1 (https=)
TW (1) TW200901987A (https=)
WO (1) WO2008130552A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2009086416A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
AU2008345097A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
AU2009286528B2 (en) * 2008-08-29 2014-07-17 Msd Italia S.R.L. Saturated bicyclic heterocyclic derivatives as Smo antagonists
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
WO2011063309A1 (en) * 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
CA2988289C (en) 2015-06-04 2023-12-05 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
CN108623446A (zh) * 2017-03-24 2018-10-09 北京艾德旺科技发展有限公司 一种合成3，3-二氟环丁烷甲酸的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) * 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
US8026264B2 (en) 2003-05-29 2011-09-27 Merck Sharp And Dohme Corp. Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
US8273743B2 (en) 2004-04-30 2012-09-25 Curis, Inc. Quinoxaline inhibitors of the hedgehog signalling
CN1993320A (zh) 2004-08-06 2007-07-04 默克公司 作为11－β－羟基类固醇脱氢酶－1的抑制剂的磺酰化合物
EP2316832B1 (en) 2004-08-27 2017-03-08 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
DK1789390T3 (da) 2004-09-02 2012-02-27 Genentech Inc Pyridyl-inhibitorer af hedgehog-signalering
CN101083996A (zh) 2004-10-28 2007-12-05 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
EP1807074B1 (en) 2004-11-03 2013-10-23 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7981910B2 (en) * 2005-10-20 2011-07-19 Merck Sharp & Dohme Corp. Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1

Also Published As

Publication number Publication date
AR066063A1 (es) 2009-07-22
US20080262051A1 (en) 2008-10-23
CN101663033A (zh) 2010-03-03
US7691887B2 (en) 2010-04-06
JP2010524937A (ja) 2010-07-22
CA2683946A1 (en) 2008-10-30
CL2008001074A1 (es) 2009-06-05
TW200901987A (en) 2009-01-16
WO2008130552A1 (en) 2008-10-30
EP2136803B1 (en) 2012-05-02
JP5498936B2 (ja) 2014-05-21
PE20090806A1 (es) 2009-06-27
CA2683946C (en) 2013-01-22
AU2008241527B2 (en) 2014-02-13
EP2136803A1 (en) 2009-12-30
AU2008241527A1 (en) 2008-10-30
ATE555785T1 (de) 2012-05-15

Similar Documents

Publication Publication Date Title
CN101663033B (zh) 作为smo拮抗剂的三唑衍生物
US20110183974A1 (en) 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as smo antagonists
AU2014219283B2 (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
KR101653548B1 (ko) 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
MD4097099T2 (ro) Agonişti GKP-1 heterociclici
TW201002683A (en) Novel substituted pyridin-2-ones and pyridazin-3-ones
KR20200081434A (ko) 파르네소이드 x 수용체 조정제로서의 가교된 비시클릭 화합물
US8470823B2 (en) Saturated bicyclic heterocyclic derivatives as SMO antagonists
JP2007535569A (ja) ヘッジホッグシグナル伝達のキノキサリン阻害剤
JP2003012653A (ja) キナゾリン誘導体
WO2010082044A1 (en) Unsaturated bicyclic heterocyclic derivatives as smo antagonists
JP2010500395A (ja) 癌治療のためのテトラヒドロピリドチオフェン誘導体
CN109721596B (zh) 苯基取代的二氢吡啶类化合物及其用途
CN105384738A (zh) 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
JP2008542242A (ja) 新規のテトラヒドロピリドチオフェン
CN113677659B (zh) 可用作类法尼醇x受体调节剂的经取代的酰胺化合物
US20130053396A1 (en) Piperidine and piperazine derivatives as smo antagonists
GB2640329A (en) Hedgehog acyltransferase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SCHERING CORP (US)

Free format text: FORMER OWNER: MSD CORP.

Effective date: 20121029

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: New jersey, USA

Applicant after: MERCK SHARP & DOHME Corp.

Address before: New jersey, USA

Applicant before: SCHERING Corp.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP.

TA01 Transfer of patent application right

Effective date of registration: 20121029

Address after: New jersey, USA

Applicant after: SCHERING Corp.

Address before: New jersey, USA

Applicant before: MERCK SHARP & DOHME Corp.

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220826

Address after: new jersey

Patentee after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Patentee before: MERCK SHARP & DOHME Corp.

TR01 Transfer of patent right